Sugi Predict

Sugi Predict / Compounds / SCHEMBL1735858

SCHEMBL1735858

SCHEMBL1735858

COc1cccc(S(=O)(=O)N2C[C@@H](C(=O)N3CCN(c4cc(Cl)ccc4C)CC3)N(c3ccccc3Cl)C2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 3/20 0.48
▸ HTT P42858 3/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ TP53 P04637 1/20 0.47
▸ TSHR P16473 7/20 0.45
▸ LMNA P02545 5/20 0.45
▸ SMN1; SMN2 Q16637 5/20 0.45
▸ MAPT P10636 4/20 0.45
▸ THRB P10828 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1735655 1.00 USP2 (0.48) USP2HTTNPSR1TP53TSHR
SCHEMBL1735854 0.94 TP53 (0.44) USP2HTTNPSR1TP53TSHR
SCHEMBL1735855 0.94 TP53 (0.44) USP2HTTNPSR1TP53TSHR
SCHEMBL1735625 0.84 MAPT (0.49) USP2HTTNPSR1TP53TSHR
SCHEMBL1735627 0.84 MAPT (0.49) USP2HTTNPSR1TP53TSHR
SCHEMBL1734770 0.84 MAPT (0.44) USP2TP53TSHRLMNASMN1; SMN2
SCHEMBL1734767 0.84 MAPT (0.44) USP2TP53TSHRLMNASMN1; SMN2
SCHEMBL1735420 0.80 KMT2A (0.49) HTTTSHRLMNASMN1; SMN2MAPT
SCHEMBL1735419 0.80 KMT2A (0.49) HTTTSHRLMNASMN1; SMN2MAPT
SCHEMBL1735421 0.79 MAPT (0.49) USP2HTTNPSR1TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 — — EP claimed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 — — WO claimed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 — — US claimed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 — — US claimed
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 — — EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 — — WO disclosed
EP-2142533-A1 IMIDAZOLIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-13 — — EP disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 — — US disclosed
WO-2008119657-A1 IMIDAZOLIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 — — WO disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 USP2 4755/4885HTT 4446/4885NPSR1 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.